Previous 10 | Next 10 |
Ligand Pharmaceuticals ( LGND +1.1% ) has acquired the economic rights to Novan's ( NOVN -0.5% ) SB206, a topical antiviral gel in Phase 3 development for skin infections, for $12M in upfront cash, up to $20M in milestones and tiered royalties of 7 - 10%. More news on: Ligand Pharmac...
Novan to immediately receive $12 million of non-dilutive capital Ligand to receive milestones and tiered royalty for North America SB206 molluscum indication Phase 3 molluscum trial to begin recruitment of patients this month Molluscum top line results targeted early during the ...
Gainers: ARCA biopharma (NASDAQ: ABIO ) +37% . MFC Bancorp (NYSE: MFCB ) +32% . Enphase Energy (NASDAQ: ENPH ) +29% . Precipio (NASDAQ: PRPO ) +25% . Nu Skin Enterprises (NYSE: NUS ) +25% . Nanometrics Incorporated (NASDAQ: NANO ) +22% . Qumu Corporation (NASDAQ: QUMU ) +22% ....
Heron Therapeutics (NASDAQ: HRTX ) -24% after FDA rejects application for pain med HTX-011. More news on: Heron Therapeutics, Inc., Nabriva Therapeutics plc, CM Seven Star Acquisition Corporation, Stocks on the move, Read more ...
May 1, 2019 Palm Beach, FL –May 1, 2019 – The consumer demand for a solution to cellulite has been growing for years. Cellulite is a cosmetic problem, not a disease process. It affects 85% to 90% of all women worldwide and 10% of men. A recent article titled “Cel...
MORRISVILLE, N.C., May 01, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq: NOVN) today confirmed that the Company will host a conference call tomorrow, Thursday, May 2, 2019 at 8:15 am Eastern Time to provide an update on the Company’s recent financing, clini...
$25 million provided immediately in exchange for participation in future potential cash flows Additional $10 million available upon achieving success in molluscum Phase 3 top line results Pipeline Priority: initiation of Phase 3 molluscum program in May 2019 with top line readout t...
March monthly performance was: +2.73% More news on: IQ 50 Percent Hedged FTSE International ETF, Rogers Corporation, Novan, Inc., Read more ...
Thinly traded nano cap Novan ( NOVN -22.4% ) is down on triple normal volume, albeit on turnover of only 203K shares, following the filing of its 2018 annual report yesterday after the close. Highlights: More news on: Novan, Inc., Healthcare stocks news, Stocks on the move, Read mo...
February monthly performance was: +2.06% More news on: IQ 50 Percent Hedged FTSE International ETF, Rogers Corporation, Novan, Inc., Read more ...
News, Short Squeeze, Breakout and More Instantly...
– The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan’s assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15 million in debtor-in-possession financing – – Progression toward...
DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will host a live audio webcast of the Company’s 2023 Annual Meeting of Stockholders (“ASM”) being held on Tuesday, June 6...
– Company directing resources on the potential approval of berdazimer gel, 10.3% (SB206) for molluscum contagiosum – – Process to explore a sale or out-license of commercial assets or other business transaction continues – – Continued progress ...